Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised Trial Comparing Trastuzumab Deruxtecan to CDK4/6 Inhibitors in Non-luminal A, ER-positive/HER2-low Metastatic Breast Cancer

NCT06585969 is registered in ClinicalTrials.gov with Danish Breast Cancer Cooperative Group as lead sponsor.

NCT NCT06585969
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06585969 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised Trial Comparing Trastuzumab Deruxtecan to CDK4/6 Inhibitors in Non-luminal A, ER-positive/HER2-low Metastatic Breast Cancer
Lead sponsor
Danish Breast Cancer Cooperative Group
Phase
Phase 3
Overall status
Withdrawn
Start date
January 1, 2026
Completion date
January 1, 2026
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

basal like, er-positive breast cancer, her2 enriched, luminal b, metastatic breast cancer